- Home
- NBB vs ORGO Comparison
NBB vs ORGO Comparison
Compare NBB & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBB
- ORGO
- Stock Information
- Founded
- NBB 2009
- ORGO 1985
- Country
- NBB United States
- ORGO United States
- Employees
- NBB N/A
- ORGO N/A
- Industry
- NBB Finance Companies
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- NBB Finance
- ORGO Health Care
- Exchange
- NBB Nasdaq
- ORGO Nasdaq
- Market Cap
- NBB 478.3M
- ORGO 474.6M
- IPO Year
- NBB N/A
- ORGO N/A
- Fundamental
- Price
- NBB $15.46
- ORGO $3.05
- Analyst Decision
- NBB
- ORGO Strong Buy
- Analyst Count
- NBB 0
- ORGO 3
- Target Price
- NBB N/A
- ORGO $5.33
- AVG Volume (30 Days)
- NBB 73.9K
- ORGO 1.1M
- Earning Date
- NBB 01-01-0001
- ORGO 11-12-2024
- Dividend Yield
- NBB 8.64%
- ORGO N/A
- EPS Growth
- NBB N/A
- ORGO N/A
- EPS
- NBB N/A
- ORGO N/A
- Revenue
- NBB N/A
- ORGO $455,038,000.00
- Revenue This Year
- NBB N/A
- ORGO $9.65
- Revenue Next Year
- NBB N/A
- ORGO $1.57
- P/E Ratio
- NBB N/A
- ORGO N/A
- Revenue Growth
- NBB N/A
- ORGO 1.34
- 52 Week Low
- NBB $13.67
- ORGO $2.17
- 52 Week High
- NBB $16.66
- ORGO $4.71
- Technical
- Relative Strength Index (RSI)
- NBB 31.06
- ORGO 35.65
- Support Level
- NBB $16.30
- ORGO $3.28
- Resistance Level
- NBB $16.50
- ORGO $3.68
- Average True Range (ATR)
- NBB 0.20
- ORGO 0.23
- MACD
- NBB -0.09
- ORGO -0.10
- Stochastic Oscillator
- NBB 5.79
- ORGO 0.00
About NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest
Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests primarily in a diversified portfolio of taxable municipal securities.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.